Business & Finance
Neurocrine Biosciences reports half-year ended 30 June 2019 financial results
30 July 2019 -

Neurocrine Biosciences Inc (NASDAQ: NBIX), a neuroscience-focused, biopharmaceutical company, announced yesterday its financial results for the six months ended 30 June 2019.

The company reported total revenues for the six months ended 30 June 2019 at USD322m compared to USD168m in the year-ago period.

The firm posted a net loss of USD50.8m or USD0.56 net loss per share for the six months ended 30 June 2019 compared to a net loss of USD47.7m or USD0.53 loss per share for the same period in 2018.

The increase in net loss for the first half of 2019 is primarily due to USD118.1m of in-process research and development (IPR&D) in connection with the strategic collaboration with Voyager. This was partially offset by increased INGREZZA net product sales and a USD22.6m unrealized gain on the company's equity investment in Voyager.